Biodesix (Nasdaq:BDSX) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BDSX Overzicht aandelen

Biodesix, Inc. is in de Verenigde Staten actief als bedrijf voor datagestuurde diagnostische oplossingen.

BDSX fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

Verhandeld tegen 86.5% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 19.69% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 76.6% zal stijgen

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft minder dan 1 jaar cash runway

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Biodesix, Inc. Concurrenten

Performant Financial

NasdaqGS:PFMT

US$269.4m

23andMe Holding

NasdaqCM:ME

US$158.4m

ModivCare

NasdaqGS:MODV

US$225.8m

Enhabit

NYSE:EHAB

US$361.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Biodesix
Historische aandelenkoersen
Huidige aandelenkoers	US$1.68
52 Week Hoogtepunt	US$2.21
52 Week Laag	US$1.15
Bèta	1.21
11 maand verandering	-9.19%
3 maanden verandering	3.70%
1 Jaar Verandering	-11.11%
33 jaar verandering	-77.54%
5 jaar verandering	n/a
Verandering sinds IPO	-86.89%

Recent nieuws en updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12

Recent updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04

Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates

Nov 25

Bearing In On Biodesix

Sep 13

Rendement voor aandeelhouders

	BDSX	US Healthcare	US Markt
7D	-5.1%	-1.3%	0.6%
1Y	-11.1%	6.6%	30.3%

Rendement versus industrie: BDSX presteerde slechter dan de US Healthcare -sector, die het afgelopen jaar een rendement van 11.3 % opleverde.

Rendement versus markt: BDSX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 33.4 % opleverde.

Prijsvolatiliteit

Is BDSX's price volatile compared to industry and market?
BDSX volatility
BDSX Average Weekly Movement	6.6%
Healthcare Industry Average Movement	7.1%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Stabiele aandelenkoers: BDSX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van BDSX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2005	217	Scott Hutton	www.biodesix.com

Biodesix, Inc. is een bedrijf in de Verenigde Staten dat zich bezighoudt met datagestuurde diagnostische oplossingen. Het bedrijf biedt longtests op basis van bloed, waaronder Nodify XL2- en Nodify CDT-tests, die samen op de markt worden gebracht als onderdeel van de Nodify Lung Nodule Risk Assessment-teststrategie, om het risico op longkanker te beoordelen en te helpen bij het identificeren van het juiste behandeltraject en artsen te helpen bij het herclassificeren van het risico op maligniteit bij patiënten met verdachte longknobbels. Het bedrijf levert ook GeneStrat ddPCR en NGS, en VeriStrat tests, die worden gebruikt bij de diagnose van longkanker om de aanwezigheid van mutaties in de tumor en de toestand van het immuunsysteem van de patiënt te meten om de prognose van de patiënt vast te stellen en beslissingen over de behandeling te helpen sturen.

Biodesix, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Biodesix zich tot de beurswaarde?
BDSX fundamentele statistieken
Marktkapitalisatie	US$245.35m
Inkomsten(TTM)	-US$44.51m
Inkomsten(TTM)	US$60.90m

4.0x

P/S-verhouding

-5.5x

Koers/Winstverhouding

Is BDSX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BDSX resultatenrekening (TTM)
Inkomsten	US$60.90m
Kosten van inkomsten	US$13.66m
Brutowinst	US$47.25m
Overige uitgaven	US$91.76m
Inkomsten	-US$44.51m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.31
Brutomarge	77.58%
Nettowinstmarge	-73.08%
Schuld/Eigen Vermogen Verhouding	98.9%

Hoe presteerde BDSX op de lange termijn?

Bekijk historische prestaties en vergelijking

BDSX Overzicht aandelen

Beloningen

Risicoanalyse

Biodesix, Inc. Concurrenten

NasdaqGS:PFMT

US$269.4m

NasdaqCM:ME

US$158.4m

NasdaqGS:MODV

US$225.8m

NYSE:EHAB

US$361.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc. Raised Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

New major risk - Shareholder dilution

Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting

Recent updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc. Raised Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

New major risk - Shareholder dilution

Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q1, 2024 Results on May 08, 2024

Biodesix, Inc., Annual General Meeting, May 21, 2024

Biodesix, Inc. announced that it expects to receive $34.999422 million in funding

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $20.000607 million.

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q4, 2023 Results on Mar 01, 2024

President notifies of intention to sell stock

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2023

Biodesix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Consensus EPS estimates upgraded to US$0.68 loss

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the Veristrat®? Blood-Based Host Immune Classifier

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Biodesix, Inc. Announces New Clinical Utility Evidence for the Nodify XL2 Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Director recently bought US$125k worth of stock

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix, Inc. Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors and Audit Committee of the Board, Effective January 3, 2023

Independent Director recently bought US$148k worth of stock

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Price target decreased to US$5.00

Biodesix, Inc. Presents New Data from the Insight Study At the 2022 Society for Immunotherapy of Cancer 37Th Annual Meeting

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Earnings Guidance for the Year 2022

Biodesix, Inc. to Report Q3, 2022 Results on Nov 03, 2022

A Second Look At Biodesix

Biodesix, Inc. Provides Revenue Guidance for the Third Quarter 2022

Biodesix expects Q3 revenue above the consensus

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2022

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Biodesix, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Biodesix, Inc.(NasdaqGM:BDSX) dropped from Russell 2000 Growth Index

Biodesix, Inc. Obtains Medicare Coverage for the Nodify CDT Lung Nodule Test